Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

423 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors.
Kostine M, Finckh A, Bingham CO, Visser K, Leipe J, Schulze-Koops H, Choy EH, Benesova K, Radstake TRDJ, Cope AP, Lambotte O, Gottenberg JE, Allenbach Y, Visser M, Rusthoven C, Thomasen L, Jamal S, Marabelle A, Larkin J, Haanen JBAG, Calabrese LH, Mariette X, Schaeverbeke T. Kostine M, et al. Among authors: haanen jbag. Ann Rheum Dis. 2021 Jan;80(1):36-48. doi: 10.1136/annrheumdis-2020-217139. Epub 2020 Apr 23. Ann Rheum Dis. 2021. PMID: 32327425 Free PMC article.
Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors.
de Moel EC, Rozeman EA, Kapiteijn EH, Verdegaal EME, Grummels A, Bakker JA, Huizinga TWJ, Haanen JB, Toes REM, van der Woude D. de Moel EC, et al. Cancer Immunol Res. 2019 Jan;7(1):6-11. doi: 10.1158/2326-6066.CIR-18-0245. Epub 2018 Nov 13. Cancer Immunol Res. 2019. PMID: 30425107
Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial.
Rini BI, Moslehi JJ, Bonaca M, Schmidinger M, Albiges L, Choueiri TK, Motzer RJ, Atkins MB, Haanen J, Mariani M, Wang J, Hariharan S, Larkin J. Rini BI, et al. J Clin Oncol. 2022 Jun 10;40(17):1929-1938. doi: 10.1200/JCO.21.01806. Epub 2022 Mar 3. J Clin Oncol. 2022. PMID: 35239416 Free PMC article.
Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, Lyon AR, Wick W, Kostine M, Peters S, Jordan K, Larkin J; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Haanen J, et al. Ann Oncol. 2022 Dec;33(12):1217-1238. doi: 10.1016/j.annonc.2022.10.001. Epub 2022 Oct 18. Ann Oncol. 2022. PMID: 36270461 Free article. No abstract available.
Immunotherapy of melanoma.
Haanen JB. Haanen JB. EJC Suppl. 2013 Sep;11(2):97-105. doi: 10.1016/j.ejcsup.2013.07.013. EJC Suppl. 2013. PMID: 26217118 Free PMC article. Review.
Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management.
Geukes Foppen MH, Rozeman EA, van Wilpe S, Postma C, Snaebjornsson P, van Thienen JV, van Leerdam ME, van den Heuvel M, Blank CU, van Dieren J, Haanen JBAG. Geukes Foppen MH, et al. Among authors: haanen jbag. ESMO Open. 2018 Jan 13;3(1):e000278. doi: 10.1136/esmoopen-2017-000278. eCollection 2018. ESMO Open. 2018. PMID: 29387476 Free PMC article. Review.
Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT).
Marabelle A, Andtbacka R, Harrington K, Melero I, Leidner R, de Baere T, Robert C, Ascierto PA, Baurain JF, Imperiale M, Rahimian S, Tersago D, Klumper E, Hendriks M, Kumar R, Stern M, Öhrling K, Massacesi C, Tchakov I, Tse A, Douillard JY, Tabernero J, Haanen J, Brody J. Marabelle A, et al. Ann Oncol. 2018 Nov 1;29(11):2163-2174. doi: 10.1093/annonc/mdy423. Ann Oncol. 2018. PMID: 30295695 Free PMC article.
423 results